A5051784163- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Dementia and Cognitive Impairment Research
- Glioma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Advanced MRI Techniques and Applications
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- MRI in cancer diagnosis
- Cancer-related cognitive impairment studies
- Health Systems, Economic Evaluations, Quality of Life
- Bladder and Urothelial Cancer Treatments
- Hormonal and reproductive studies
- Ovarian cancer diagnosis and treatment
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Medical Imaging and Pathology Studies
- Cancer, Hypoxia, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Functional Brain Connectivity Studies
- Neuroendocrine Tumor Research Advances
- Global Cancer Incidence and Screening
University of California, Los Angeles
2020-2025
Molecular Theranostics (United States)
2020-2025
Magna Graecia University
2023-2025
VA Greater Los Angeles Healthcare System
2024
LMU Klinikum
2023
Ludwig-Maximilians-Universität München
2023
Stanford University
2016-2022
UCLA Health
2020-2022
Imaging Center
2022
Ronald Reagan UCLA Medical Center
2021
The impact of prostate-specific membrane antigen (PSMA) PET/CT on management prostate cancer (PCa) patients with biochemical recurrence (BCR) is well established. However, whether and how PSMA affects the undergoing scans for other clinical indications remains unknown. goal this study was to determine <sup>68</sup>Ga-PSMA-11 initial subsequent decisions in a cohort PCa referred various (i.e., basket trial) excluding 2 main classic indications: BCR presurgical staging. <b>Methods:</b> This...
The role of prostate-specific membrane antigen (PSMA)-targeted PET in comparison to mpMRI the evaluation intraprostatic cancer foci is not well defined. aim our study was compare diagnostic performances PSMA PET/CT, and PET/CT+mpMRI using 3 independent blinded readers for each modality with histopathology as gold standard detection, intra-prostatic localization local extension primary prostate cancer. <b>Methods:</b> Patients intermediate- or high-risk who underwent a PET/CT part prospective...
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy can improve the outcome of patients with advanced metastatic castration-resistant prostate cancer, but do not respond uniformly. We hypothesized that using salivary glands as a reference organ enable selective patient stratification. aimed to establish PSMA PET tumor–to–salivary gland ratio (PSG score) predict outcomes after [<sup>177</sup>Lu]PSMA. <b>Methods:</b> In total, 237 men cancer treated [<sup>177</sup>Lu]PSMA...
<sup>68</sup>Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH<sub>2</sub> (<sup>68</sup>Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer (PCa). We present data from the use of <sup>68</sup>Ga-RM2 patients with biochemical recurrence (BCR) PCa and negative findings on conventional imaging. <b>Methods:</b>...
To characterize individual and group-level neuroimaging findings in patients at risk for Chronic Traumatic Encephalopathy (CTE). Eleven male meeting criteria Syndrome (TES, median age: 64) underwent neurologic evaluation, 3-Tesla MRI, PET with [18F]-Flortaucipir (FTP, tau-PET) [11C]-Pittsburgh compound B (PIB, amyloid-PET). Six [18F]-Fluorodeoxyglucose-PET (FDG, glucose metabolism). We assessed imaging the patient level, comparisons modality-specific groups of cognitively normal older adults...
A newly introduced PET/CT scanner (Discovery Meaningful Insights-DMI, GE Healthcare) includes the silicon photomultiplier (SiPM) with time-of-flight (TOF) technology first used in SIGNA PET/MRI. In this study, we investigated impact of various acquisition times on image quality using SiPM-based PET/CT. We reviewed data from 58 participants cancer who were scanned DMI scanner. The administered dosages ranged 295.3-429.9 MBq (mean ± SD 356.3 37.4) and imaging started at 71-142 min 101.41...
Quantitative 3-T multiparametric MRI parameters correlated with and helped predict the presence of aggressive large cribriform pattern intraductal carcinoma prostate cancer at whole-mount histopathology.
344 Background: PSMA PET imaging is a highly sensitive and specific tool for detecting prostate cancer, especially in biochemical recurrence (BCR). This has led to growing interest utilizing patients with minimally detectable PSA levels following definitive treatment as conventional rarely localizes recurrent disease this range, potentially delaying diagnosis appropriate management. However, there limited literature on the detection rate of 18F-DCFPyL at very low BCR setting. Methods: pooled...
40 Background: After primary definitive therapy of localized prostate cancer with either radical prostatectomy or radiation therapy, up to 50% patients will experience biochemical recurrence (BCR) disease. The objective this descriptive, retrospective analysis is compare the performance PSMA PET/CT and pelvic MRI in BCR investigate added value their combined use patient population. Methods: Patients who underwent within three months each other at University California, Los Angeles available...
338 Background: Micro-Ultrasound (MicroUS) is a new imaging modality capable of identifying prostate cancer (PCa). Prior evaluation MicroUS and multiparametric MRI (MRI) have demonstrated comparable accuracy but are limited by relying on biopsy pathology for ground truth. There no available studies that comprehensively evaluate the diagnostic extraprostatic extension (EPE) MicroUS, MRI, PSMA PET/CT (PSMA) against wholemount histopathology (WMHP) as reference. Methods: Patients with PCa who...
To demonstrate the potential value of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) as a rapid, non-invasive metabolic imaging surrogate for pharmacological modulation EGFR signaling in EGFR-driven GBM, we synchronously conducted preclinical study using patient-derived orthotopic xenograft (PDOX) models and validated it phase II molecular recurrent GBM (rGBM) patients osimertinib. A PDOX mouse model was performed concurrently with an open-label, single-arm, single-center,...
The aim of this study was to analyze the patterns prostate bed (PB) recurrence in cancer patients experiencing prostate-specific antigen (PSA) persistence (BCP) or biochemical (BCR) after radical prostatectomy using <sup>68</sup>Ga-PSMA-11 PET/CT (<sup>68</sup>Ga-PSMA PET) relation Radiation Therapy Oncology Group (RTOG) clinical target volumes (CTVs). <b>Methods:</b> This single-center, retrospective analysis included with BCP BCR and PB on <sup>68</sup>Ga-PSMA PET. recurrences were...
Introduction Positron emission tomography targeting tau (tau-PET) is a promising diagnostic tool for the identification of Alzheimer's disease (AD). Currently available data rely on quantitative measures, and visual interpretation method, critical clinical translation, needed. Methods We developed method 18F-flortaucipir tau-PET tested it 274 individuals (cognitively normal controls, patients with mild cognitive impairment [MCI], AD dementia, non-AD diagnoses). Two readers interpreted PET...
<sup>18</sup>F-(E)-<i>N</i>-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′methylphenyl)nortropane (<sup>18</sup>F-FE-PE2I) is a newly developed dopamine transporter (DAT) PET radioligand. Full quantification methods rely on dynamic acquisition of <sup>18</sup>F-FE-PE2I, but in clinical setting simplified protocol preferable. The aims this study were to identify the optimal time window for <sup>18</sup>F-FE-PE2I and validate specific binding ratio (SBR) as method. <b>Methods:</b> Ten...
Background Understanding the characteristics of multiparametric MRI (mpMRI) in patients from different racial/ethnic backgrounds is important for reducing observed gaps clinical outcomes. Purpose To investigate diagnostic performance mpMRI and quantitative parameters prostate cancer (PCa) African American (AA) matched White (W) men. Study Type Retrospective. Subjects One hundred twenty‐nine (43 AA, 86 W) with histologically proven PCa who underwent before radical prostatectomy. Field...